Short Interest in Pfenex Inc (PFNX) Increases By 13.4%
Pfenex Inc (NYSEAMERICAN:PFNX) was the recipient of a large increase in short interest in the month of December. As of December 29th, there was short interest totalling 198,379 shares, an increase of 13.4% from the December 15th total of 174,975 shares. Currently, 1.0% of the company’s shares are short sold. Based on an average daily trading volume, of 721,971 shares, the short-interest ratio is currently 0.3 days.
PFNX has been the topic of several research analyst reports. JMP Securities reduced their price objective on shares of Pfenex from $21.00 to $8.00 and set an “outperform” rating on the stock in a report on Friday, November 10th. Zacks Investment Research upgraded shares of Pfenex from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $5.50.
A number of large investors have recently modified their holdings of PFNX. Susquehanna International Group LLP acquired a new position in shares of Pfenex during the second quarter worth about $272,000. Legal & General Group Plc grew its position in shares of Pfenex by 2,567.5% during the second quarter. Legal & General Group Plc now owns 110,249 shares of the biotechnology company’s stock worth $442,000 after buying an additional 106,116 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Pfenex by 186.0% during the second quarter. Goldman Sachs Group Inc. now owns 160,204 shares of the biotechnology company’s stock worth $642,000 after buying an additional 104,184 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Pfenex by 112.1% during the second quarter. Dimensional Fund Advisors LP now owns 201,066 shares of the biotechnology company’s stock worth $806,000 after buying an additional 106,257 shares in the last quarter. Finally, C WorldWide Group Holding A S grew its position in shares of Pfenex by 10.5% during the third quarter. C WorldWide Group Holding A S now owns 271,400 shares of the biotechnology company’s stock worth $820,000 after buying an additional 25,900 shares in the last quarter.
Shares of Pfenex (NYSEAMERICAN:PFNX) opened at $3.45 on Friday. The stock has a market cap of $79.59, a PE ratio of -1.94 and a beta of 3.95. Pfenex has a one year low of $2.07 and a one year high of $9.39.
Pfenex (NYSEAMERICAN:PFNX) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.17. The company had revenue of $5.02 million for the quarter, compared to analyst estimates of $3.30 million. Pfenex had a negative net margin of 175.52% and a negative return on equity of 63.57%. The business’s revenue for the quarter was down 89.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.46 earnings per share.
Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.